HUP0200447A2 - Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection - Google Patents

Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Info

Publication number
HUP0200447A2
HUP0200447A2 HU0200447A HUP0200447A HUP0200447A2 HU P0200447 A2 HUP0200447 A2 HU P0200447A2 HU 0200447 A HU0200447 A HU 0200447A HU P0200447 A HUP0200447 A HU P0200447A HU P0200447 A2 HUP0200447 A2 HU P0200447A2
Authority
HU
Hungary
Prior art keywords
ribavirin
rna
infection
patients
chronic hepatitis
Prior art date
Application number
HU0200447A
Other languages
English (en)
Inventor
Frank Bennett
Ashit K Ganguly
Viyyoor M Girijavallabhan
Raymond G Lovey
Jinping Mccormick
Anil K Saksena
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0200447A2 publication Critical patent/HUP0200447A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HU0200447A 1998-10-16 1999-10-14 Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection HUP0200447A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
HUP0200447A2 true HUP0200447A2 (en) 2002-06-29

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200447A HUP0200447A2 (en) 1998-10-16 1999-10-14 Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Country Status (20)

Country Link
EP (1) EP1121369B1 (hu)
JP (1) JP2002527522A (hu)
CN (1) CN1330658A (hu)
AT (1) ATE284408T1 (hu)
AU (1) AU762395B2 (hu)
BR (1) BR9915546A (hu)
CA (1) CA2346447C (hu)
CZ (1) CZ20011130A3 (hu)
DE (1) DE69922529T2 (hu)
ES (1) ES2229820T3 (hu)
HU (1) HUP0200447A2 (hu)
ID (1) ID29187A (hu)
IL (1) IL142423A0 (hu)
NO (1) NO20011789L (hu)
NZ (1) NZ510811A (hu)
PL (1) PL347268A1 (hu)
RU (1) RU2001113268A (hu)
SK (1) SK4742001A3 (hu)
TR (1) TR200101085T2 (hu)
WO (1) WO2000023454A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
EP1660116A4 (en) * 2003-08-13 2008-04-30 Smith Howard J & Ass Pty Ltd METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
WO2007027230A2 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
EP2201953A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER
EP2198870A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp ACTIVATOR FOR BLOOD COAGULATION FACTOR VII PROMOTER AND USE THEREOF
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107925A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
CN117355311A (zh) 2022-05-05 2024-01-05 阿卜杜拉·库尔卡耶夫 用于恢复生物体生理过程和细胞的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
EP0942916A2 (en) * 1996-11-12 1999-09-22 Medivir Aktiebolag Nucleosides

Also Published As

Publication number Publication date
ATE284408T1 (de) 2004-12-15
CA2346447C (en) 2006-01-31
AU762395B2 (en) 2003-06-26
ES2229820T3 (es) 2005-04-16
CN1330658A (zh) 2002-01-09
PL347268A1 (en) 2002-03-25
DE69922529D1 (de) 2005-01-13
WO2000023454A1 (en) 2000-04-27
TR200101085T2 (tr) 2001-08-21
EP1121369A1 (en) 2001-08-08
BR9915546A (pt) 2001-08-14
NO20011789L (no) 2001-06-11
NO20011789D0 (no) 2001-04-09
RU2001113268A (ru) 2003-09-27
EP1121369B1 (en) 2004-12-08
ID29187A (id) 2001-08-09
DE69922529T2 (de) 2005-12-15
IL142423A0 (en) 2002-03-10
SK4742001A3 (en) 2001-11-06
JP2002527522A (ja) 2002-08-27
CA2346447A1 (en) 2000-04-27
NZ510811A (en) 2003-06-30
AU1197500A (en) 2000-05-08
CZ20011130A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
HK1016505A1 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
AU1197600A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
HUP0200447A2 (en) Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
AU2001255495A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
HUP0102033A3 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
GB2341804B (en) Improvements in or relating to hypodermic syringes
GB2334513B (en) Modular casket
HUP0103186A3 (en) Disposable article having bodily waste component sensor
DK1223997T3 (da) Medicinsk infusionssæt
HUP0103526A3 (en) Catheter set
EP0707855A3 (en) Combination therapy for chronic hepatitis C infection
HUP0103150A3 (en) Disposable absorbant article
TW428436U (en) Disposable trunks-type pants
GB2294867B (en) Disposable bibs
AU5577299A (en) Disposable bib
TW345007U (en) Absorbent article having inflected barrier cuffs
GB9820804D0 (en) ANSI syringe
ATA196898A (de) Zahnputzkörper
GB9819222D0 (en) Improvements relating to medical syringes
ZA984470B (en) Medical syringe
DK0850632T3 (da) Læge eller tandlægebehandlingsplads med en behandlingsstol
AU137377S (en) Disposable stretcher
KR960024164U (ko) 호신봉
GB9826012D0 (en) Catheter keeper